Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11271816 | 0.92 | KMT2A (0.48) | KMT2AMEN1TSHRSLC6A3SLC6A4 | |
| SCHEMBL22261511 | 0.86 | ALDH1A1 (0.53) | KMT2AMEN1TSHRKDM4EMAPT | |
| SCHEMBL1610957 | 0.85 | KMT2A (0.55) | KMT2AMEN1TSHRKDM4EMAPT | |
| SCHEMBL7130530 | 0.84 | SLC6A4 (0.47) | KMT2AMEN1TSHRSLC6A3SLC6A4 | |
| SCHEMBL27294758 | 0.83 | HCRTR1 (0.40) | KMT2AMEN1TSHRKDM4EMAPT | |
| SCHEMBL12320666 | 0.83 | KMT2A (0.53) | KMT2AMEN1TSHRKDM4EMAPT | |
| SCHEMBL20235825 | 0.81 | NR4A2 (0.60) | KMT2AMEN1SLC6A3SLC6A4KDM4E | |
| SCHEMBL12922048 | 0.81 | CYP46A1 (0.57) | KMT2AMEN1TSHRKDM4EMAPT | |
| SCHEMBL20850165 | 0.81 | MAPT (0.53) | KMT2AMEN1SLC6A3SLC6A4KDM4E | |
| SCHEMBL27825552 | 0.81 | DNMT1 (0.53) | KMT2AMEN1KDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100582088-C | Aminoalcohol derivatives | ASTELLAS PHARMA INC | 2010-01-20 | — | — | CN | disclosed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| CN-1906154-A | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-01-31 | — | — | CN | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
| CN-1626532-A | Amide compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | CN | disclosed |
| CN-1170826-C | Amide compound | ����ҩƷ��ҵ��ʽ���� | 2004-10-13 | — | — | CN | disclosed |
| CN-1376153-A | Amide compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | KMT2A 2913/4885MEN1 1950/4885TSHR 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.